Abstract
Effective salvage chemotherapy for patients with ovarian cancer who have failed platinum- and taxane-based regimens has not been identified. It has been reported that prolonged infusions of chemotherapy may be active in some malignancies which have become refractory to bolus treatments. We evaluated a regimen of 96-hr continuous-infusion doxorubicin (10 mg/m2/24 hr), etoposide (50 mg/m2/24 hr), and bolus cyclophosphamide (750 mg/m2) administered every 21 days to patients with ovarian cancer who had previously been treated with paclitaxel and a platinum compound. Nineteen women were treated, 15 of whom had platinum-refractory cancer. Six of the first 9 experienced a neutropenic fever after the first treatment cycle, and therefore all subsequent patients received prophylactic granulocyte-colony-stimulating factor. Other significant toxicities included hand and foot syndrome (1 patient) and mucositis (4 patients). There was one partial response in a patient with platinum-sensitive disease. We conclude that this regimen causes significant myelosuppression and does not have major activity in heavily pretreated patients with ovarian cancer.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Adult
-
Aged
-
Antibiotics, Antineoplastic / administration & dosage
-
Antibiotics, Antineoplastic / adverse effects
-
Antibiotics, Antineoplastic / therapeutic use*
-
Antineoplastic Agents, Alkylating / administration & dosage
-
Antineoplastic Agents, Alkylating / adverse effects
-
Antineoplastic Agents, Alkylating / therapeutic use*
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / therapeutic use*
-
Dose-Response Relationship, Drug
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Doxorubicin / therapeutic use*
-
Drug Therapy, Combination
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Etoposide / therapeutic use*
-
Female
-
Fever / prevention & control
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
Humans
-
Infusions, Intravenous
-
Injections
-
Middle Aged
-
Ovarian Neoplasms / drug therapy*
-
Salvage Therapy
-
Time Factors
Substances
-
Antibiotics, Antineoplastic
-
Antineoplastic Agents, Alkylating
-
Antineoplastic Agents, Phytogenic
-
Granulocyte Colony-Stimulating Factor
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide